Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Shares Outstanding (Weighted Average) (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $93.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 25.21% year-over-year to $93.0 million, compared with a TTM value of $93.0 million through Dec 2025, up 25.21%, and an annual FY2025 reading of $93.0 million, up 25.21% over the prior year.
  • Shares Outstanding (Weighted Average) was $93.0 million for Q4 2025 at aTYR PHARMA, down from $97.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $97.2 million in Q3 2025 and bottomed at $14.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $51.7 million, with a median of $52.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 108.3% in 2021, then increased 22.17% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $19.1 million in 2021, then soared by 48.94% to $28.4 million in 2022, then soared by 88.63% to $53.6 million in 2023, then surged by 38.53% to $74.3 million in 2024, then rose by 25.21% to $93.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ATYR at $93.0 million in Q4 2025, $97.2 million in Q3 2025, and $88.3 million in Q2 2025.